Sanofi recalls all lots of Allerject (0.15 mg/0.15 mL and 0.3 mg/0.3 mL strengths)
What you need to know:
Sanofi-aventis Canada Inc., in consultation with Health Canada, is recalling all lots of Allerject (0.15 mg/0.15mL and 0.3 mg/0.3 mL strength epinephrine auto-injectors) from the Canadian market.
Allerject is a medication delivery device that prescribed to adults and children diagnosed with severe allergic reactions, and is used as an emergency treatment.
This recall is due to issues that may potentially affect the delivery of the required amount of the drug, epinephrine.
This means that individuals may not receive a full dose of the medication from the recalled Allerject devices.
The affected lot numbers are as follows:
- Allerject Pre-filled Autoinjector (DIN02382059 – 0.15mg/0.15mL epinephrine)
- Allerject Pre-filled Autoinjector (DIN02382067 – 0.3mg/0.3mL epinephrine)
What should you do?
Health Canada is advising anyone with an Allerject device (0.15 mg/0.15 mL and 0.3 mg/0.3 mL strengths) to return the device to the pharmacy where they initially got it to receive a replacement epinephrine auto-injector with the same dose.
For those affected by this recall, Health Canada is also advising that in the event that a life-threatening allergic reaction (anaphylaxis) occurs before you can obtain a replacement auto injector, use your Allerject device as directed by your healthcare provider, and then seek emergency medical attention.
Speak with your healthcare professional if you are concerned about your health or your child’s health.
Report any adverse events to Health Canada.
For more information, or to report an adverse event, please visit the Health Canada website.